查詢結果分析
相關文獻
- 末期慢性腎衰竭高磷血症用藥
- 腎臟替代療法在兒科的臨床應用
- The Significance of Syphilis Serology Tests on Long-Term Hemodialysis Patients
- Watermelon Stomach--An Unusual Cause of Recurrent Upper Gastrointestinal Bleeding in a Uremic Patient Receiving Estrogen-Progesterone Therapy: Case Report
- Serum Transferrin Receptor Concentration is Not Indicative of Erythropoietic Activity in Chronic Hemodialysis Patients with Poor Response to Recombinant Human Erythropoietin
- 血液透析患者飲食習慣之調查
- 透析病患的心臟血管疾病
- 透析患者的腦血管疾病
- 血液透析動靜脈瘻管的竊血症候群
- 血液透析病人的中央靜脈狹窄
頁籤選單縮合
題 名 | 末期慢性腎衰竭高磷血症用藥=Treatment of Hyperphosphatemia in Chronic Kidney Disease |
---|---|
作 者 | 吳雀維; 林政仁; 吳勝文; | 書刊名 | 藥學雜誌 |
卷 期 | 29:2=115 2013.06[民102.06] |
頁 次 | 頁97-100 |
分類號 | 418.22 |
關鍵詞 | 高磷血症; 磷酸鹽結合劑; 透析; Sevelamer hydrochloride; Lanthanum carbonate; |
語 文 | 中文(Chinese) |
中文摘要 | 末期慢性腎臟病透析病人大多數必然的後果是產生高磷血症。其往往會增加透析病人心血管疾病的死亡率1。飲食控制和目前透析方式,並不能全部且有效地維持血中磷酸鹽在適當的範圍之內,故許多的透析病人需要口服磷酸鹽結合劑來降低血中磷酸鹽濃度。 目前所使用的磷結合劑以含鈣或含鋁為主流,其雖然可有效控制血中磷的濃度,但因長期使用所衍生的後遺症,對長期透析病人會造成更大的傷害。 含鋁之磷結合劑被腸胃道吸收後,長期累積在人體內會造成病人腦病變、骨病變和貧血等後遺症已經被證明。長期使用含鈣之磷結合劑,亦會造成高鈣血症,產生血管鈣化。因此,對長期透析病人而言,需要一種無鈣、無鋁及可有效控制高血清磷症之磷結合劑是必要的。 Sevelamer hydrochloride (磷能解) 和 lanthanum carbonate (碳酸鑭) 都是屬非鋁、鈣的磷酸鹽黏結劑。相對而言是其副作用較少,不過兩者都成本較高,對病人而言實在是一筆不小的負擔。 |
英文摘要 | Hyperphosphatemia often occurs in advanced chronic kidney disease patients on dialysis. The hyperphosphatemia increase the risk of cardiovascular mortality in dialysis patients. Dietary restriction of phosphate and current dialysis modalities could be ineffective in maintaining serum phosphate within the appropriate range, so the majority of dialysis patients require oral phosphate binders. Currently used phosphate binders, mainly containing calcium or aluminum can effectively control the concentration of phosphorus in the blood, however, long-term use could be harmful. Aluminum-containing phosphate binder is absorbed by the gastrointestinal tract. Aluminum accumulate in human body will result in brain dementia, bone disorder, and anemia. Long-term use of calcium-containing phosphate binders is associated with hypercalcemia and vascular calcification. Therefore, non-calcium and non-aluminum-containing phosphate binder is necessary for long-term dialysis patients with hyperphosphatemia. Sevelamer hydrochloride and lanthanum carbonate are non-aluminum and non-calcium containing phosphate binder, and have few side effects, however, the high cost limits their wide clinical use. |
本系統中英文摘要資訊取自各篇刊載內容。